Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1395, but it redirected us to https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1395. The analysis below is for the second page.

Title[redir]:
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo | Breast Cancer Research | Full Text
Description:
Introduction The ras pathway is essential for cell growth and proliferation. The effects of R115777, a farnesyl transferase inhibitor, were investigated in cancer cell lines expressing varying levels of growth factor receptors and with differing ras status. Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested. Method In vitro, the concentrations required to reduce cell numbers by 50% (50% inhibitory concentration) were established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474, SK-BR3 and SKOV3). Human DCIS was implanted in nude mice or, in separate experiments, cultured cells were injected (MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form tumours. Proliferation and apoptosis were determined by immunohistochemistry in xenografts and cell tumours. Results The 50% inhibitory concentrations varied a hundred-fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 μmol/l(± 0.8 μmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells the levels of tumour growth inhibition were approximately 85% and 40%, respectively. There was a significant decrease in the cell turnover index (CTI; proliferation/apoptosis). In MDA-MB 231 with activated k-ras no inhibition was observed. In treated DCIS xenografts proliferation decreased and apoptosis increased. The CTI ratio between the start and 1 and 2 weeks of treatment were 1.99 and 1.50, respectively, for controls and 0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts. Conclusion Treatment with the farnesyl transferase inhibitor reduced cell growth in vitro and cell tumour growth in vivo. In DCIS treatment resulted in a reduced CTI. R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established.

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🚄 Respectable Traffic: 10k - 20k visitors per month


Based on our best estimate, this website will receive around 10,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cell, cancer, tumours, growth, breast, ras, pubmed, google, scholar, treated, cas, tumour, dcis, article, treatment, mgkg, xenografts, experiments, human, inhibition, study, control, transferase, effect, farnesyl, proliferation, protein, vitro, day, cells, vivo, fti, mcfher, res, apoptosis, cti, lines, index, table, inhibitor, mice, line, carcinoma, reduced, authors, data, pathway, factor, results, controls,

Topics {✒️}

springer nature carboxyl-terminal tetrapeptide caax expressed wild-type k-ras tamoxifen-resistant tumorigenic growth eosin stained sections final tumour volume 1309/4ncm-qj9w-qm0j-6qje mda-mb231 cell lines mda-mb231 cell line mitogen-activated protein kinase authors scientific editing proliferation index/apoptotic index materials body weight loss/gain activated wild-type ras wild-type ras proteins authors’ original file wild-type ras cancer final histopathological report farnesyl transferase inhibitor mouse received tissue farnesyl transferase inhibition privacy choices/manage cookies comedo-type ductal carcinoma median tumour volume de klerk gj enzyme farnesyl transferase cell turnover index bmc farnesyl transferase inhibitors final manuscript dose-ranging pharmacodynamic study unchanged apoptotic index ras proto-oncogene activation treated mcf-7/her2-18 tumours mutated k-ras protein transferase blocks cell lines considered skov3 cell tumours farnesyl tranferase inhibition mcf-7/her2-18 cells treated author correspondence mcf-7/her2-18 control tumours mcf-7 cell line mcf-7/her2-18 tumours grown 1465-542x contact activated k-ras k-rasbv12 proteins wild-type ras [11–13] wild-type ras

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
         description:The ras pathway is essential for cell growth and proliferation. The effects of R115777, a farnesyl transferase inhibitor, were investigated in cancer cell lines expressing varying levels of growth factor receptors and with differing ras status. Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested. In vitro, the concentrations required to reduce cell numbers by 50% (50% inhibitory concentration) were established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474, SK-BR3 and SKOV3). Human DCIS was implanted in nude mice or, in separate experiments, cultured cells were injected (MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form tumours. Proliferation and apoptosis were determined by immunohistochemistry in xenografts and cell tumours. The 50% inhibitory concentrations varied a hundred-fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 μmol/l(± 0.8 μmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells the levels of tumour growth inhibition were approximately 85% and 40%, respectively. There was a significant decrease in the cell turnover index (CTI; proliferation/apoptosis). In MDA-MB 231 with activated k-ras no inhibition was observed. In treated DCIS xenografts proliferation decreased and apoptosis increased. The CTI ratio between the start and 1 and 2 weeks of treatment were 1.99 and 1.50, respectively, for controls and 0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts. Treatment with the farnesyl transferase inhibitor reduced cell growth in vitro and cell tumour growth in vivo. In DCIS treatment resulted in a reduced CTI. R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established.
         datePublished:2006-04-12T00:00:00Z
         dateModified:2006-04-12T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr1395
         keywords:
            Apoptotic Index
            SKOV3 Cell
            Farnesyl Transferase Inhibition
            R115777 Treatment
            Final Tumour Volume
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1395/MediaObjects/13058_2006_1369_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1395/MediaObjects/13058_2006_1369_Fig2_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Fredrik Wärnberg
               affiliation:
                     name:Breast Biology Group, Christie Hospital NHS Trust
                     address:
                        name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
                     name:South Manchester University Hospital
                     address:
                        name:Department of Pathology, South Manchester University Hospital, Manchester, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daniel White
               affiliation:
                     name:Breast Biology Group, Christie Hospital NHS Trust
                     address:
                        name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elizabeth Anderson
               affiliation:
                     name:Breast Biology Group, Christie Hospital NHS Trust
                     address:
                        name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fiona Knox
               affiliation:
                     name:South Manchester University Hospital
                     address:
                        name:Department of Surgery, South Manchester University Hospital, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert B Clarke
               affiliation:
                     name:Breast Biology Group, Christie Hospital NHS Trust
                     address:
                        name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julie Morris
               affiliation:
                     name:South Manchester University Hospital
                     address:
                        name:Department of Medical Statistics, South Manchester University Hospital, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nigel J Bundred
               affiliation:
                     name:South Manchester University Hospital
                     address:
                        name:Department of Pathology, South Manchester University Hospital, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
      description:The ras pathway is essential for cell growth and proliferation. The effects of R115777, a farnesyl transferase inhibitor, were investigated in cancer cell lines expressing varying levels of growth factor receptors and with differing ras status. Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested. In vitro, the concentrations required to reduce cell numbers by 50% (50% inhibitory concentration) were established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474, SK-BR3 and SKOV3). Human DCIS was implanted in nude mice or, in separate experiments, cultured cells were injected (MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form tumours. Proliferation and apoptosis were determined by immunohistochemistry in xenografts and cell tumours. The 50% inhibitory concentrations varied a hundred-fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 μmol/l(± 0.8 μmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells the levels of tumour growth inhibition were approximately 85% and 40%, respectively. There was a significant decrease in the cell turnover index (CTI; proliferation/apoptosis). In MDA-MB 231 with activated k-ras no inhibition was observed. In treated DCIS xenografts proliferation decreased and apoptosis increased. The CTI ratio between the start and 1 and 2 weeks of treatment were 1.99 and 1.50, respectively, for controls and 0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts. Treatment with the farnesyl transferase inhibitor reduced cell growth in vitro and cell tumour growth in vivo. In DCIS treatment resulted in a reduced CTI. R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established.
      datePublished:2006-04-12T00:00:00Z
      dateModified:2006-04-12T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr1395
      keywords:
         Apoptotic Index
         SKOV3 Cell
         Farnesyl Transferase Inhibition
         R115777 Treatment
         Final Tumour Volume
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1395/MediaObjects/13058_2006_1369_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1395/MediaObjects/13058_2006_1369_Fig2_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Fredrik Wärnberg
            affiliation:
                  name:Breast Biology Group, Christie Hospital NHS Trust
                  address:
                     name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
                  name:South Manchester University Hospital
                  address:
                     name:Department of Pathology, South Manchester University Hospital, Manchester, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daniel White
            affiliation:
                  name:Breast Biology Group, Christie Hospital NHS Trust
                  address:
                     name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elizabeth Anderson
            affiliation:
                  name:Breast Biology Group, Christie Hospital NHS Trust
                  address:
                     name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fiona Knox
            affiliation:
                  name:South Manchester University Hospital
                  address:
                     name:Department of Surgery, South Manchester University Hospital, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert B Clarke
            affiliation:
                  name:Breast Biology Group, Christie Hospital NHS Trust
                  address:
                     name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julie Morris
            affiliation:
                  name:South Manchester University Hospital
                  address:
                     name:Department of Medical Statistics, South Manchester University Hospital, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nigel J Bundred
            affiliation:
                  name:South Manchester University Hospital
                  address:
                     name:Department of Pathology, South Manchester University Hospital, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:8
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Breast Biology Group, Christie Hospital NHS Trust
      address:
         name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
         type:PostalAddress
      name:South Manchester University Hospital
      address:
         name:Department of Pathology, South Manchester University Hospital, Manchester, UK
         type:PostalAddress
      name:Breast Biology Group, Christie Hospital NHS Trust
      address:
         name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
         type:PostalAddress
      name:Breast Biology Group, Christie Hospital NHS Trust
      address:
         name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
         type:PostalAddress
      name:South Manchester University Hospital
      address:
         name:Department of Surgery, South Manchester University Hospital, Manchester, UK
         type:PostalAddress
      name:Breast Biology Group, Christie Hospital NHS Trust
      address:
         name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
         type:PostalAddress
      name:South Manchester University Hospital
      address:
         name:Department of Medical Statistics, South Manchester University Hospital, Manchester, UK
         type:PostalAddress
      name:South Manchester University Hospital
      address:
         name:Department of Pathology, South Manchester University Hospital, Manchester, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Fredrik Wärnberg
      affiliation:
            name:Breast Biology Group, Christie Hospital NHS Trust
            address:
               name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
               type:PostalAddress
            type:Organization
            name:South Manchester University Hospital
            address:
               name:Department of Pathology, South Manchester University Hospital, Manchester, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daniel White
      affiliation:
            name:Breast Biology Group, Christie Hospital NHS Trust
            address:
               name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
               type:PostalAddress
            type:Organization
      name:Elizabeth Anderson
      affiliation:
            name:Breast Biology Group, Christie Hospital NHS Trust
            address:
               name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
               type:PostalAddress
            type:Organization
      name:Fiona Knox
      affiliation:
            name:South Manchester University Hospital
            address:
               name:Department of Surgery, South Manchester University Hospital, Manchester, UK
               type:PostalAddress
            type:Organization
      name:Robert B Clarke
      affiliation:
            name:Breast Biology Group, Christie Hospital NHS Trust
            address:
               name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
               type:PostalAddress
            type:Organization
      name:Julie Morris
      affiliation:
            name:South Manchester University Hospital
            address:
               name:Department of Medical Statistics, South Manchester University Hospital, Manchester, UK
               type:PostalAddress
            type:Organization
      name:Nigel J Bundred
      affiliation:
            name:South Manchester University Hospital
            address:
               name:Department of Pathology, South Manchester University Hospital, Manchester, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
      name:Department of Pathology, South Manchester University Hospital, Manchester, UK
      name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
      name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
      name:Department of Surgery, South Manchester University Hospital, Manchester, UK
      name:Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
      name:Department of Medical Statistics, South Manchester University Hospital, Manchester, UK
      name:Department of Pathology, South Manchester University Hospital, Manchester, UK

Social Networks {👍}(2)

External Links {🔗}(329)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.08s.